Onxeo changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023
All the resolutions approved by the Board of Directors were adopted Paris (France), June 6, 2023 – 6:30 pm […]
Combined General Meeting of June 6, 2023: availability of preparatory documents and participation & voting procedures
Paris (France), May 16, 2023 – 06:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company […]
Publication of the 2022 Annual Financial Report
Paris (France), April 28, 2023 – 9.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter “Onxeo” or the […]
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates
Phase 1b/2 trial of AsiDNATM in combination with olaparib in the United States in recurrent ovarian, breast and metastatic castration-resistant […]
Onxeo will publish its full-year results on April 24, 2023
Paris (France), April 21, 2023 – 8:30 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company […]
Onxeo will publish its full-year results on April 14, 2023
The annual general meeting will be held on June 6, 2023 Paris (France), March 14, 2023 – 6:00 pm […]
Onxeo will publish its full-year results on April 21, 2023
Paris (France), April 14, 2023 – 5:35 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company […]
Onxeo: report on the Extraordinary General Meeting of February 6, 2023
Paris (France), February 6, 2023 – 7:30 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), […]
ONXEO provides update on the Development Program for its first-in-class drug candidate AsiDNATM
Phase 1b/2 trial of AsiDNATM in combination with olaparib initiated in the United States in recurrent ovarian, breast and metastatic […]
Onxeo advances its second lead candidate OX425 for the treatment of solid tumors
OX425 is a novel DDR Decoy Agonist which also mediates multiple immunostimulatory effects, making it a promising candidate for combination […]
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities
Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally Cash position of €26.9 million as of June […]
High-Grade Glioma Relapse in Children: Onxeo announces the enrollment of the first patient in the phase 1b/2 clinical study conducted by the European ITCC consortium and sponsored by Institut Curie
Paris (France), September 1st, 2022 – 8 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North[1]: ONXEO), a […]
Combined General Meeting of August 17, 2022: Onxeo shareholders approve withdrawal from the Nasdaq First North market in Copenhagen
Company to submit delisting request to Nasdaq Paris (France), August 17, 2022 – 08:00 pm CEST – Onxeo S.A. […]
Combined General Meeting of August 17, 2022: availability of preparatory documents and participation & voting procedures
Paris (France), July 29, 2022 – 06:30 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a […]
Onxeo announces a Combined General Meeting on August 17, 2022
Paris (France), July 12, 2022 – 07:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
Initial IND application for AsiDNA Granted “Study May Proceed” by the U.S. FDA
Onxeo to initiate its first phase 1b/2 trial in the United States in patients with solid tumors Paris (France), […]
AACR Annual Meeting 2022 (April 8 – 13, 2022)
AACR Annual Meeting 2022 (April 8 – 13, 2022)
Combined General Meeting (April 19, 2020 | 2:00 pm)
Extraordinary General Meeting (April 19, 2020 | 2:00 pm)
Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022
All resolutions voted in accordance with Board of Directors’ recommendations Khalil Barrage, Managing Director of Invus’ public equity investments division, […]
Publication of the 2021 Annual Financial Report
Paris (France), April 28, 2022 – 6.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer
Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]
Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million
Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]
Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022
AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]
Onxeo appoints Julien Miara as new interim CEO
Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]
Onxeo Announces its Financial Agenda for 2022
Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]
Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors
These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022 Paris (France), March 9, 2022 – 7:00 […]